IGKV1-5 Antikörper

Produktnummer ABIN7115198

Der Kaninchen Polyklonal Anti-IGKV1-5-Antikörper wurde für WB und ELISA validiert. Er ist geeignet, IGKV1-5 in Proben von Human und Maus zu detektieren.

Kurzübersicht für IGKV1-5 Antikörper (ABIN7115198)

Target: IGKV1-5 (Immunoglobulin kappa Variable 1-5 (IGKV1-5))

Reaktivität: Human, Maus

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser IGKV1-5 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA

Produktdetails anti-IGKV1-5 Antikörper

Verwendungszweck: IGKV1-5 antibody

Aufreinigung: Immunogen affinity purified

Reinheit: ≥95 % as determined by SDS-PAGE

Immunogen: immunoglobulin kappa variable 1-5

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB: 1:500-1:2000

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: PBS with 0.02 % sodium azide and 50 % glycerol pH 7.3,

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freeze / thaw cycles.

Lagerung: -20 °C

Informationen zur Lagerung: -20°C for 12 months

Haltbarkeit: 12 months

Details zu IGKV1-5

Target: IGKV1-5 (Immunoglobulin kappa Variable 1-5 (IGKV1-5))

Andere Bezeichnung: IGKV1-5

Hintergrund:

Synonyms: Immunoglobulin kappa variable 1-5|Ig kappa chain V-I region CAR|Ig kappa chain V-I region EU|Ig kappa chain V-I region HK102|Ig kappa chain V-I region Kue|IGKV1-5

Background: V segment of the variable domain of immunoglobulins light chain that participates to the antigen recognition. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens(PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen(PubMed:20176268, PubMed:17576170).

UniProt: P01602